QureTech Bio announces prestigious investment from Kempestiftelserna
September 23, 2024
QureTech Bio, a biotechnology company developing novel antibiotics, today announced a substantial investment from Kempestiftelserna. This investment enables QureTech Bio to continue its mission to develop innovative therapies that address the urgent global challenge of antimicrobial resistance.
With this financial support, QureTech Bio will be able to accelerate its research and development efforts of novel antibiotic treatments and bringing life-saving treatments closer to those who need them most. A total of SEK 14 million was invested in the company by Kempestiftelserna along with the company’s largest shareholder Nascent Invest.
The investment will specifically support QureTech Bio’s groundbreaking work in targeting infectious bacteria that have become resistant to conventional antibiotics. By leveraging cutting-edge technology and scientific expertise, the company is poised to make significant advancements in the field of antimicrobial resistance.
“We are happy to welcome such a reputable foundation as Kempestiftelserna as a shareholder,” says Markus Thor, CEO of QureTech Bio. “Their investment makes a true difference and is a testament to the importance of our work and the potential impact it can have on global health. This investment will enable us to accelerate our development programs.“
“We believe in the innovative approach of QureTech Bio and are proud to support the company’s efforts in fighting antimicrobial resistance,” comments Alice Kempe, Chairman of the board at Kempestiftelserna. “This partnership reflects our commitment to fostering advancements in medical research at and around Umeå University and thereby improving public health.”
Contact
Markus Thor, CEO
E-mail: markus.thor@quretech.com
Telephone: +46 73-520 40 35
Web: www.quretech.com
About QureTech Bio
QureTech Bio AB (QTB) is a biotechnology company developing new solutions to combat disease-causing bacteria to tackle one of our times’ greatest health threats, antimicrobial resistance (AMR). The company’s lead program is focused on developing a new class of antibiotics, called GmPcides, that are effective against multidrug resistant Gram-positive bacteria. QTB is located in Umeå in one of Sweden’s most vibrant life science clusters.
About Kempestiftelserna
Kempestiftelserna are two foundations committed to supporting groundbreaking research and initiatives in Västerbotten, Norrbotten and Västernorrland that have a meaningful impact on society. Through funding of academic research and, in a limited number of cases, by supporting selected strategic projects and companies, the foundations aim to foster innovation and drive progress in various fields, including healthcare, education, and technology.